NCT06375343
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved 1 year 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jan 30, 2027 to Mar 30, 2028 Show 5 more changesShow less
- Start date: Jan 30, 2026 to Jul 30, 2027
- Eligibility criteria expanded, about 32 words
- Study completion pushed from Jan 30, 2027 to Apr 30, 2028
- Secondary endpoints: details revised at 5 of 7 entries
- Study description expanded, about 7 words
- Notable Primary and study completion dates pushed to Jan 30, 2027
- Start date: Oct 30, 2024 to Jan 30, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of unexpected adverse events related to the interventions
Timeframe: Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)
Secondary (7)
Changes in the Ocular Comfort Index score
Adherence to treatment (adherence) Adherence to treatment (adherence)
Changes in Best Corrected Visual Acuity (BCVA)
Changes in tear film breakup time
Changes in intraocular pressure (IOP)
Show 2 moreShow less
Changes in the integrity of the ocular surface (fluorescein staining)
Changes in lissamine green staining of the conjunctival surface
Arms and interventions
PRO-240Experimental
* Propylene glycol 0.3% - Polyethylene glycol 400 0.5% - Glycerin 0.2%. Ophthalmic solution. * Dosage: 1 drop QID \[4\] (four times per day) for 7 days in both eyes. * Route of administration: Ophthalmic
Optive®Active comparator
* Carboxymethylcellulose 0.5%; Glycerin 0.9%. Ophthalmic solution. * Dosage: 1 drop QID \[4\] (four times per day) for 7 days in both eyes. * Route of administration: Ophthalmic
Drugs: PRO-240, Optive®